AlphAIAlphAI — Financial news for AI agents
investing.comSEP 12 min read

Truist raises Callaway Golf stock price target on self-help factors

Truist Securities raised its price target for Callaway Golf (NYSE:ELY) to $20.00 from $19.00, citing self-help factors like SKU rationalization and store closures. The stock is up 64% over the past year. Callaway reported Q2 2026 earnings of $0.39 per share, beating estimates, with revenue of $612.2 million and a 36% increase in adjusted EBITDA.

Original reporting
investing.com
Published Sep 1, 2026, 3:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 1, 2026, 4:55 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
MARKET
Neutral
AI market analysis
Mentioned
$CALY
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

Med
01

Why it matters

The upgrade could trigger short‑term buying pressure, but investors should monitor upcoming earnings for confirmation.

02

Market read

Analyst upgrade adds modest upside potential for Callaway Golf and may influence sector sentiment.

03

What to watch

Potential headwinds from discretionary spending slowdown and competition from lower‑priced brands.

Relevance 7/10Novelty 7/10Timing: Monday (report date)

Background

Truist highlighted lower‑margin SKU rationalization, store closures, and stock repurchases as catalysts.

Market effects

Sector

Positive signal for the golf equipment sector as margin improvements may be echoed by peers.

Regional

U.S. consumer discretionary stocks could see modest uplift.

Global

Limited to markets tracking U.S. consumer discretionary equities.

Counterpoint

What could challenge this read

The price target raise may be premature if margin gains are not sustainable.

Key entities

  • analyst
    Truist Securities

    Equity research firm that issued the price target raise.

  • company
    Callaway Golf

    Manufacturer of golf equipment, ticker ELY.

Read at source← All news

Related articles

AUG 4
$CALYMed

CALLAWAY GOLF COMPANY ANNOUNCES SECOND QUARTER 2026 RESULTS

Callaway Golf Co (CALY) filed an SEC Form 8-K — Results of Operations and Financial Condition. CALLAWAY GOLF COMPANY ANNOUNCES SECOND QUARTER 2026 RESULTS Second Quarter Net Sales (+2%), GAAP Net Income from Continuing Operations (+67%) and Adjusted EBITDA (+36%) Raises Full-Year Guidance HIGHLIGHTS • Q2 GAAP and Non-GAAP Gross Margin increased 620 basis points and 460 bas

SEC EDGAR 8-K6 min
OCT 8
$RCLHigh

Jefferies upgrades Royal Caribbean stock rating on improved revenue outlook

Jefferies upgraded Royal Caribbean (RCL) to Buy with a $330 price target, citing improved occupancy and revenue per passenger. RCL trades at $282.32, with a P/E ratio of 17.66. Jefferies raised revenue estimates for Q3 2026 and FY 2027, projecting net yield growth and higher EBITDA. Despite lower EPS estimates, the firm increased valuation multiples. Other analysts also upgraded RCL, citing strategic developments and positive yield outlooks.

investing.com2 min
OCT 8
$NGNEHigh

JPMorgan initiates Neurogene stock rating at Overweight on gene therapy potential

JPMorgan initiated coverage on Neurogene Inc. (NASDAQ: NGNE) with an Overweight rating and a $60.00 price target, citing potential in its gene therapy NGN-401 for Rett syndrome. The stock trades at $25.87, with analysts maintaining a Strong Buy consensus. Neurogene expects key data readouts in 2H27, with a market cap of $518 million and high volatility. Recent analyst adjustments include lowered price targets from H.C. Wainwright and Canaccord, both maintaining Buy ratings.

investing.com2 min
OCT 8
$BHVNMed

Biohaven Enters Strategic Licensing Agreement with Ono Pharma for Extracellular IgG Degraders in Japan and Select Asian Regions, Lead Candidate BHV-1300 in Phase 3 for Graves' Disease

Biohaven (BHVN) has entered a licensing agreement with Ono Pharma for its extracellular IgG degraders in Japan and select Asian regions. Biohaven will receive up to $100 million in payments, including $80 million upfront, and 20% royalties on net sales. The lead candidate, BHV-1300, is in Phase 3 trials for Graves' disease. Biohaven retains rights to the portfolio outside the licensed territory.

prnewswire.com2 min